Targeted Medical Pharma, Inc.: 10-Q filed 2012-11-14
What Targeted Medical Pharma, Inc. reported in its quarterly report filed 2012-11-14 (fiscal Q3 2012): 34 published measures, 99 facts as tagged in accession 0001144204-12-062471.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-11-14
- Fiscal period
- fiscal Q3 2012
- Accession
- 0001144204-12-062471 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Targeted Medical Pharma, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 11,063,776 | USD | |
| At 2011-12-31 | 8,977,776 | USD | |
| At 2011-09-30 | 7,627,293 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 13,534,088 | USD | |
| At 2011-12-31 | 8,370,343 | USD | |
| At 2011-09-30 | 6,697,945 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | -2,470,312 | USD | |
| At 2011-12-31 | 607,433 | USD | |
| At 2011-09-30 | 929,348 | USD | |
| At 2010-12-31 | 3,291,270 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 4,210 | USD | |
| At 2011-12-31 | 147,364 | USD | |
| At 2011-09-30 | 3,574 | USD | |
| At 2010-12-31 | 795,914 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -1,241,443 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -5,042,183 | USD | 274 |
| 2011-01-01 to 2011-12-31 | -4,177,050 | USD | 365 |
| 2011-07-01 to 2011-09-30 | -1,282,998 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -2,806,184 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | -2,598,013 | USD | 274 |
| 2011-01-01 to 2011-09-30 | -1,996,529 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 111,862 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 83,819 | USD | 273 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 2,076,532 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 4,899,943 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 2,458,998 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 6,869,255 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 2,712,500 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 1,534,948 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | -257,641 | USD | 274 |
| 2011-01-01 to 2011-09-30 | -330,759 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | -9,140,795 | USD | |
| At 2011-12-31 | -4,098,612 | USD | |
| At 2011-09-30 | -2,727,746 | USD |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -0.06 | USD/shares | 92 |
| 2011-01-01 to 2011-09-30 | -0.13 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2011-09-30 | -0.06 | USD/shares | 92 |
| 2011-01-01 to 2011-09-30 | -0.13 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 384,217 | USD | |
| At 2011-12-31 | 411,823 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 562,981 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 661,750 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -1,507,629 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -4,775,858 | USD | 274 |
| 2011-07-01 to 2011-09-30 | -1,458,430 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -3,890,549 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 2,906,135 | USD | |
| At 2011-12-31 | 2,899,717 | USD | |
| At 2011-09-30 | 2,253,427 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 12,167,809 | USD | |
| At 2011-12-31 | 7,483,293 | USD | |
| At 2011-09-30 | 5,861,837 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 554,053 | USD | |
| At 2011-12-31 | 899,493 | USD | |
| At 2011-09-30 | 879,036 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 2,467,865 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 7,303,510 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 3,163,910 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 8,793,891 | USD | 273 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 854,202 | USD | |
| At 2011-12-31 | 495,821 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 960,236 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 2,527,652 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 1,705,480 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 4,903,342 | USD | 273 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 2,431,049 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 7,209,421 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 3,113,310 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 8,674,171 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | 36,816 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 94,089 | USD | 274 |
| 2011-07-01 to 2011-09-30 | 50,600 | USD | 92 |
| 2011-01-01 to 2011-09-30 | 119,720 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 22,049,576 | shares | |
| At 2011-12-31 | 21,949,576 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 6,648,433 | USD | |
| At 2011-12-31 | 4,684,095 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 2,347,880 | USD | |
| At 2011-12-31 | 2,387,801 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-09-30 | 46,000 | USD | |
| At 2011-12-31 | 26,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -1,241,443 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -5,042,183 | USD | 274 |
| 2011-07-01 to 2011-09-30 | -1,282,998 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -2,809,393 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 325,167 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 336,885 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -315,810 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -2,258,467 | USD | 274 |
| 2011-07-01 to 2011-09-30 | -583,739 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -576,101 | USD | 273 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-07-01 to 2012-09-30 | -581,996 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -1,992,142 | USD | 274 |
| 2011-07-01 to 2011-09-30 | -759,171 | USD | 92 |
| 2011-01-01 to 2011-09-30 | -1,660,466 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | -345,440 | USD | 274 |
| 2011-01-01 to 2011-09-30 | 423,578 | USD | 273 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-09-30 | 358,381 | USD | 274 |
| 2011-01-01 to 2011-09-30 | -36,582 | USD | 273 |
Inspect the source
- Entity
- Targeted Medical Pharma, Inc. / CIK 0001420030
- Captured
- SEC response SHA-256
ca03716eae22460fbd50b309d17f5dd90795ea400593e50d5768fd8934ffb155
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001420030.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))